Trial reportEuropean heart journal. Cardiovascular Imaging2017
Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction.
Trial report in European heart journal. Cardiovascular Imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Right atrial volume index and right atrial volume predict atrial fibrillation recurrence: A meta-analysis.PloS one · 2024Pooled it
- Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.The Cochrane database of systematic reviews · 2021Pooled it
- Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.The Cochrane database of systematic reviews · 2018Pooled it
- Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.JACC. Heart failure · 2018Trial
- Factors Associated with Atrial Fibrillation in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: A Real-World Cohort Study.Journal of clinical medicine · 2026Article
- The Prognostic Role of the Left Atrium in Hypertensive Patients with HFpEF: Does Function Matter More than Structure?Life (Basel, Switzerland) · 2025Article
- Four-dimensional echocardiographic quantification of left atrial function in metabolic syndrome across different diastolic function states.BMC cardiovascular disorders · 2025Article
- Atrial Fibrillation Among ICU Patients with Type 2 Respiratory Failure: Who Is at Risk and What Are the Outcomes?Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Imaging for Risk Stratification in Atrial Fibrillation with Heart Failure.Cardiology clinics · 2019Review
- High Incidence of Short-term Subsequent Atrial Fibrillation Following Restrictive Filling Mitral Flow Profile in Patients without Structural Heart Disease.Journal of cardiovascular echographyArticle
- A Long Atrial Electromechanical Interval is Associated with Arrhythmic Recurrence after Catheter Ablation: How to Find What Has Been Lost.Journal of cardiovascular echographyArticle
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
aimsTo determine if markers of diastolic dysfunction are associated with atrial fibrillation (AF) development among patients with heart failure with preserved ejection fraction (HFpEF). METHODS AND
resultsWe examined the association of several echocardiographic measures of diastolic dysfunction with incident AF in 573 patients (mean age = 68 ± 9.5 years; 48% men; 79% white) with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT) who were free of baseline AF. Echocardiograms were analysed at a core laboratory. Incident AF cases were identified by follow-up study electrocardiograms and review of relevant medical records through May of 2013. Over a median follow-up of 3 years, 40 patients developed AF (incidence rate = 2.2 per 100 person years). Increasing values of the E/A ratio [per 0.1 increase: hazard ratio (HR) = 1.11, 95% confidence interval (CI) = 1.06-1.17], left atrial volume (per 5 mL increase: HR = 1.13, 95% CI = 1.03-1.23), and left atrial area (per 5 cm2 increase: HR = 1.51, 95% CI = 1.03-2.22) were associated with greater risk of AF. The risk of AF decreased with increasing peak A wave velocities (per 10 cm/s increase: HR = 0.83, 95% CI = 0.72-0.96). The risk of AF was not materially altered when peak A wave velocity was further adjusted for left atrial volume (HR = 0.83, 95% CI = 0.71-0.96) and area (HR = 0.83, 95% CI = 0.71-0.96). However, the associations of left atrial volume (HR = 1.10, 95% CI = 0.99-1.22) and area (HR = 1.48, 95% CI = 0.96-2.28) were no longer significant when accounting for peak A wave velocity.
conclusionDiastolic parameters of left atrial function possibly are more important markers of AF risk than left atrial dilation in HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.